MedTrace Logo

Effect of Indomethacin on the Progression of Alzheimer's Disease

NCT00432081 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2007-02-06

No results posted yet for this study

Summary

The purpose of this study is determine whether indomethacin is able to retard disease progression in patients with mild to moderate Alzheimer's disease.

Conditions

  • Alzheimer Disease

Interventions

DRUG

indomethacin

Sponsors & Collaborators

  • American Health Assistance Foundation

    collaborator OTHER

  • Netherlands Brain Foundation

    collaborator OTHER

  • Netherlands Alzheimer Foundation

    collaborator OTHER

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Rene WM Jansen, MD, PhD · Radboud University Medical Center Nijmegen

  • Berry PH Kremer, MD, PhD · Radboud University Medical Center Nijmegen

  • Danielle De Jong, MD · Radboud University Medical Center Nijmegen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-05-31
Completion
2005-08-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00432081 on ClinicalTrials.gov